Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.3%

1 terminated/withdrawn out of 19 trials

Success Rate

93.8%

+7.2% vs industry average

Late-Stage Pipeline

11%

2 trials in Phase 3/4

Results Transparency

1 of 15 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

3(37.5%)

N/A

2(25.0%)

Phase 4

1(12.5%)

Phase 2

1(12.5%)

Phase 3

1(12.5%)

8Total

Phase 1(3)

N/A(2)

Phase 4(1)

Phase 2(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT06572982Not ApplicableActive Not Recruiting

Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients

Role: lead

NCT06326697Phase 1Completed

Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)

Role: lead

NCT00404989Recruiting

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.

Role: collaborator

NCT05282108Recruiting

Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia

Role: lead

NCT05423769Completed

Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt

Role: lead

NCT03625388Phase 2Completed

Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Role: lead

NCT04468165Completed

Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region

Role: lead

NCT05563818Completed

Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia

Role: lead

NCT04246021Not ApplicableCompleted

Use of Intravenous Ferric Carboxymaltose in Treatment of Anemia in Cancer Patients Undergoing Chemotherapy

Role: collaborator

NCT04854538Phase 1Completed

Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France)

Role: collaborator

NCT03454503Completed

Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

Role: lead

NCT03452501Completed

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

Role: lead

NCT04657744Phase 1Completed

Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).

Role: collaborator

NCT03460678Phase 4Terminated

Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.

Role: lead

NCT03348046Completed

Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan

Role: lead

NCT03517982Completed

Generic Mycophenolate Mofetil Safety Study for Prophylaxis in de Novo Renal Transplant Patients in Jordan

Role: lead

NCT03516955Completed

Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting